References
- Wallence E, Lyndon W, Chumley P, et al. Dasatinib-induced nephrotic-range proteinuria. Am J Kidney Dis 2013; 61: 1026–1031.
- Ruebner RL, Copelovitch L, Evageliou NF, et al. Nephrotic syndrome associated with tyrosine kinase inhibitors for pediatric malignancy: case series and review of the literature. Pediatr Nephrol 2014; 5: 863–869.
- Haznedaroglu IC. Current concerns of undertreatment and overtreatment in chronic myeloid leukemia based on European LeukemiaNet 2013 recommendation. Expert Opin Pharmacother 2013; 14: 2005–2010.
- Sung HJ, Lee SR, Park Y, et al. Imatinib mesylate dose adjustment based on body surface area for CKL chronic phase patients intolelant to standard dosage. Acta Haematol 2015; 134: 59–68.
- Jha PK, Vankalakunti M, Siddini V, et al. Sunitinib induced nephrotic syndrome and thrombotic microangiopathy. Indian J Nephrol 2013; 1: 67–70.
- Pallotti MC, Pantaleo MA, Nannini M, et al. R: development of a nephrotic syndrome in a patient with gastrointestinal stromal tumor during a long-time treatment with sunitinib. Case Rep Oncol 2012; 5: 651–656.
- Takashi D, Nagahama K, Tsuure Y, et al. Sunitinib induced nephrotic syndrome and irreversible renal dysfunction. Clin Exp Nephrol 2012; 16: 310–315.
- Baek SH, Kim H, Lee J, et al. Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea. Korean J Intern Med 2014; 29: 40–48.
- Malkan UY, Gunes G, Etgul S, et al. Management of de novo CML and imatinib-induced acute rhabdomyolysis with the second-generation TKI, dasatinib. Ann Pharmacol 2015; 49: 740–742.
- Giles FJ, O’Dwyer M, Sword R. Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1698–1707.